Possible role of EMID2 on nasal polyps pathogenesis in Korean asthma patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pasaje, Charisse Flerida Arnejo | - |
dc.contributor.author | Bae, Joon Seol | - |
dc.contributor.author | Park, Byung-Lae | - |
dc.contributor.author | Cheong, Hyun Sub | - |
dc.contributor.author | Kim, Jeong-Hyun | - |
dc.contributor.author | Jang, An-Soo | - |
dc.contributor.author | Uh, Soo-Taek | - |
dc.contributor.author | Park, Choon-Sik | - |
dc.contributor.author | Shin, Hyoung Doo | - |
dc.date.accessioned | 2021-08-12T03:45:24Z | - |
dc.date.available | 2021-08-12T03:45:24Z | - |
dc.date.issued | 2012-01-04 | - |
dc.identifier.issn | 1471-2350 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/15417 | - |
dc.description.abstract | Background: Since subepithelial fibrosis and protruded extracellular matrix are among the histological characteristics of polyps, the emilin/multimerin domain-containing protein 2 (EMID2) gene is speculated to be involved in the presence of nasal polyps in asthma and aspirin-hypersensitive patients. Methods: To investigate the association between EMID2 and nasal polyposis, 49 single-nucleotide polymorphisms (SNPs) were genotyped in 467 asthmatics of Korean ancestry who were stratified further into 114 aspirin exacerbated respiratory disease (AERD) and 353 aspirin-tolerant asthma (ATA) subgroups. From pairwise comparison of the genotyped polymorphisms, 14 major haplotypes (frequency > 0.05) were inferred and selected for association analysis. Differences in the frequency distribution of EMID2 variations between polyp-positive cases and polyp-negative controls were determined using logistic analyses. Results: Initially, 13 EMID2 variants were significantly associated with the presence of nasal polyps in the overall asthma group (P = 0.0008-0.05, OR = 0.54-1.32 using various modes of genetic inheritance). Although association signals from 12 variants disappeared after multiple testing corrections, the relationship between EMID2_BL1_ht2 and nasal polyposis remained significant via a codominant mechanism (P-corr = 0.03). On the other hand, the nominal associations observed between the genetic variants tested for the presence of nasal polyps in AERD (P = 0.003-0.05, OR = 0.25-1.82) and ATA (P = 0.01-0.04, OR = 0.46-10.96) subgroups disappeared after multiple comparisons, suggesting lack of associations. Conclusions: These preliminary findings suggest that EMID2_BL1_ht2 may be a susceptibility marker of inflammation of the nasal passages among Korean asthma patients. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BioMed Central | - |
dc.title | Possible role of EMID2 on nasal polyps pathogenesis in Korean asthma patients | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/1471-2350-13-2 | - |
dc.identifier.scopusid | 2-s2.0-84855293877 | - |
dc.identifier.wosid | 000301072100001 | - |
dc.identifier.bibliographicCitation | BMC Medical Genetics, v.13 | - |
dc.citation.title | BMC Medical Genetics | - |
dc.citation.volume | 13 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.subject.keywordPlus | ASPIRIN-INTOLERANCE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | FAMILY | - |
dc.subject.keywordPlus | POWER | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.